Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours Nov 28, 2025 12:00AM
Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL Jul 14, 2025 12:31AM
Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma) Sep 3, 2024 08:30AM
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort Apr 15, 2024 04:09PM
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 Apr 9, 2024 12:00PM


Mar 11, 2024 11:39AM Phase 1 onCARlytics solid tumour trial advances to combination arm treatment
Feb 22, 2024 10:10AM Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
Feb 6, 2024 08:30AM RenovoRx CEO Issues Letter to Shareholders
Dec 11, 2023 06:30PM NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments
Nov 14, 2023 08:30AM RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
Oct 2, 2023 08:30AM RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
Aug 17, 2023 08:30AM RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights
Jul 31, 2023 08:30AM RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
Jul 20, 2023 08:00AM RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
Jun 28, 2023 06:30AM Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
Nov 10, 2022 05:00PM Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
May 17, 2022 07:00PM City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors
Mar 14, 2022 07:32PM Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer
Nov 18, 2021 11:00AM City of Hope Opens Oncolytic Virus Clinical Trial for Patients With Advanced Breast Cancer
Nov 17, 2021 01:05AM Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer
Nov 1, 2021 08:00AM Imugene and Eureka Therapeutics Announce Strategic Collaboration to Accelerate Advancement of Oncolytic Virus and T-Cell Therapy in Solid Tumours
Aug 4, 2021 07:00PM Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors
May 18, 2021 09:00AM Imugene Licenses Cd19 Oncolytic Virus From City of Hope to Turn Car T Therapy Against Solid Tumors
Jul 15, 2019 09:29AM Imugene Enhances Portfolio with Compelling Oncolytic Virus from City of Hope, a Cancer Centre in Los Angeles, California